Video

OligoPilot™ Oligonucleotide Synthesizer Product Overview

Source: Cytiva

The OligoPilot™ oligonucleotide synthesizer is a high-performance system designed for early to mid-phase clinical trials and diagnostic kit production, offering synthesis scales ranging from 10 to 150 mmol. With a compact footprint that fits in a walk-in fume hood, it provides a robust and scalable solution for oligonucleotide manufacturing.

Seamless Scale-Up: Uses UNICORN™ control software, enabling smooth transition from ÄKTA™ oligopilot™ plus to full-scale manufacturing with the OligoProcess™ system.

  • Fast Coupling: Supports one batch per day, allowing for high-throughput synthesis. With trained personnel and efficient SOPs, the system can be part of a production workflow generating over 100 kg of oligonucleotides annually.
  • Process Control & Monitoring: Inline monitoring provides real-time process control, ensuring precision and reproducibility.
  • Proven Reliability: Built on over 30 years of oligonucleotide pharma expertise and utilizing the same robust components as the OligoProcess™ synthesizer.
  • Regulatory & Compliance Support: Offers Installation and Operation Qualification (IQ/OQ) documentation, performance support, and change control notifications to meet industry standards.
  • Compact & Safe Design: Fits in walk-in fume hoods and is explosion-proof according to ATEX Zone 2 regulations (check local legislation for compliance).

The UNICORN™ software ensures synchronized control across synthesis, chromatography, and filtration, supporting an efficient and streamlined oligonucleotide development and manufacturing process.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development